Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development

R. Scott Duncan 1, Bob Song 1 and Peter Koulen 1,2,*

1 Vision Research Center, Department of Ophthalmology, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA; duncanrs@umkc.edu (R.S.D.); bsong1993@gmail.com (B.S.)
2 Department of Biomedical Science, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA
* Correspondence: koulenp@umkc.edu; Tel.: +1-816-404-1834

Received: 21 April 2018; Accepted: 28 May 2018; Published: 31 May 2018

Abstract: A major cause underlying familial Alzheimer’s disease (AD) are mutations in presenilin proteins, presenilin 1 (PS1) and presenilin 2 (PS2). Presenilins are components of the γ-secretase complex which, when mutated, can affect amyloid precursor protein (APP) processing to toxic forms of amyloid beta (Aβ). Consequently, presenilins have been the target of numerous and varied research efforts to develop therapeutic strategies for AD. The presenilin 1 gene harbors the largest number of AD-causing mutations resulting in the late onset familial form of AD. As a result, the majority of efforts for drug development focused on PS1 and Aβ. Soon after the discovery of the major involvement of PS1 and PS2 in γ-secretase activity, it became clear that neuronal signaling, particularly calcium ion (Ca2+) signaling, is regulated by presenilins and impacted by mutations in presenilin genes. Intracellular Ca2+ signaling not only controls the activity of neurons, but also gene expression patterns, structural functionality of the cytoskeleton, synaptic connectivity and viability. Here, we will briefly review the role of presenilins in γ-secretase activity, then focus on the regulation of Ca2+ signaling, oxidative stress, and cellular viability by presenilins within the context of AD and discuss the relevance of presenilins in AD drug development efforts.

Keywords: γ-secretase; amyloid beta; calcium signaling; drug target discovery; endoplasmic reticulum; inositol 1,4,5-trisphosphate receptor; ion channel; oxidative stress; ryanodine receptor; therapy

1. Introduction

Presenilins have long been known to play a role in familial Alzheimer’s disease (AD) pathogenesis [1]. With two presenilin genes in vertebrates, homologs of the human genes PSEN1 and PSEN2, the two resulting presenilin proteins, presenilin 1 (PS1) and presenilin 2 (PS2) [1] are constituents of the multi-subunit γ-secretase complex which facilitates proteolytic processing of amyloid precursor protein (APP) [2]. Mutations in APP lead to accumulation of amyloid-beta peptides (Aβ), which can be toxic to neural tissue and contribute to AD pathology in the brain [2] with recent studies indicating that the formation of annular protofibrils by Aβ leads to membrane permeabilization and subsequent dysregulation of ion homeostasis [3]. PS1, specifically, is associated with familial AD in part by influencing Ca2+ signaling [4], yet there is still much to be uncovered about presenilins with new studies revealing more about non-canonical (non-γ-secretase–related) functions. Here, we discuss the role of PS1 and PS2 in cellular oxidative stress, in protein degradation/autophagy, and in
regulating intracellular endoplasmic reticulum (ER) Ca\(^{2+}\) channels (i.e., inositol 1,4,5-trisphosphate receptors (IP\(_3\)Rs) and ryanodine receptors (RyRs)). Investigating this involvement of presenilins in Ca\(^{2+}\) signaling results in unique challenges due to the ubiquitous expression of IP\(_3\)Rs and RyRs by a wide range of cell types in almost every tissue and organ. This challenge also represents a unique opportunity for drug target discovery and clinical drug development efforts by taking advantage of recently identified mechanisms that place presenilins at the crossroads of oxidative stress, calcium signaling, and neuronal viability. Combining such insights with the newly identified role of presenilin involvement in neuronal calcium signaling represents novel opportunities in drug development for Alzheimer’s disease, the focus of the present review.

2. \(\gamma\)-Secretase Activity of Presenilin

The role of presenilins, APP and \(\gamma\)-secretase in AD pathogenesis has been widely studied. Presenilin proteins, PS1 and PS2, are constituents of the \(\gamma\)-secretase complex, which carry out amyloid precursor protein (APP) proteolytic processing [2]. Three new novel PS1 mutations have been uncovered in patients with a vast heterogeneity of clinical phenotypes [5]. Investigation of wild-type \(\gamma\)-secretase with six familial Alzheimer’s disease (FAD) mutants in PS1 and five FAD mutants in the A\(\beta\) peptide segment of the APP revealed that all mutations were associated with decreased \(\gamma\)-secretase activity and a reduced age of disease onset and death [6]. Furthermore, an increase in the ratio between A\(\beta\) expression and \(\gamma\)-secretase activity was an early sign of disease in both sporadic and familial AD [6]. The PS2 K115Efx10 mutation causes PS2 protein truncation, and resembles a PS2 isoform, PS2V, which is found in late onset AD brains [7]. Additionally, PS2V mutants were able to activate \(\gamma\)-secretase activity which, under hypoxic conditions, correlated with an attenuation of the unfolded protein response [7].

Mature PS1 has many distinct conformational states while non-mature PS1 has only one state [8]. Structural studies of PS1 reveal a so-called “gate-plug” structure where the site responsible for endo-proteolytic cleavage is found. Transmembrane 5 and 6 regions (TM5 and TM6) make up the gate while the exon 9 loop region of the protein makes up the plug. A so-called “unplugging mechanism” by endo-proteolysis and subsequent removal of exon 9 loop is associated with the mature PS1, and susceptibility of a gate-plug region to conformational changes may indicate how PS1 mutants initiate disease [8]. Diminished access and inaccurate cleavage of substrate, along with the altered gate-plug activity, may explain why PS1 mutations are correlated with reduced A\(\beta\) levels and increase in A\(\beta\)\(_{42}\):A\(\beta\)\(_{40}\) ratio [8]. Changes to TM5 and TM6 histidines (H171A and H197A) reduce self-cleavage of PS1 and interaction with additional \(\gamma\)-secretase constituents, leading to reduced A\(\beta\) generation [9].

Substitution of histidines with lysine residues in TM5 and TM6 yields structurally normal \(\gamma\)-secretase complexes however with defective enzymatic activity [9].

Saturation of \(\gamma\)-secretase with substrate may mechanistically underlie AD pathogenesis by increasing the A\(\beta\)\(_{42}\):A\(\beta\)\(_{40}\) ratio, suggesting that competitive \(\gamma\)-secretase inhibitors may be potential therapeutics for AD [10]. Noncompetitive inhibitors, on the other hand, may worsen AD by promoting APP saturation [10]. Two conserved AXAXAXXG motifs were identified in PS1 and PS2, and their involvement in \(\gamma\)-secretase complex configuration were found to be involved in the alternation between normal and pathological \(\gamma\)-secretase conformations [11].

Small molecule \(\gamma\)-secretase modulators were investigated as potential therapies for AD by reducing A\(\beta\)\(_{42}\) while not blocking \(\gamma\)-secretase processing of substrates [12]. Using a photo-affinity probe, E2012-BPyne, that specifically labeled the N-terminus of PS1 within the active \(\gamma\)-secretase, but not the full-length PS1 in the active form, \(\gamma\)-secretase displayed several binding sites with separate functions [12].

The subcellular localization of \(\gamma\)-secretase has been investigated as a contributing factor to A\(\beta\) production. The protein Retention in Endoplasmic Reticulum 1 (RER1) controls the intracellular trafficking of \(\gamma\)-secretase [13]. While overexpression of RER1 results in decreased localization of \(\gamma\)-secretase to the cell surface and decreased secretion of A\(\beta\) secretion, knockdown of RER1 in turn
increased both levels of γ-secretase on the cell surface and Aβ secretion [13]. All in all, increased RER1 decreases the mature APP form leading to reduced surface APP accumulation [13].

Mice engineered to express wild type or mutant PS1 in the central nervous system (CNS) and HEK293 cells engineered to express PS paralogs revealed γ-secretase interactions with synaptic vesicle complexes and fusion to cellular membranes as well as H+ transporting lysosomal ATPase complex [14]. The peptidase was mainly co-purified with γ-secretase complexes containing PS2 to control Aβ production [14].

The roles of γ-secretase orthologs from other species have provided clues to non-canonical γ-secretase functions. For example, Dictyostelium discoideum γ-secretase orthologs can proteolytically process ectopically expressed human APP to yield Aβ peptides (Aβ40 and Aβ42), but γ-secretase-deficient strains cannot generate Aβ peptides [15]. Dictyostelium γ-secretase was also found to be important for phagocytosis and cell fate determination. These data suggest that phagocytosis may require an active γ-secretase in mammalian and Dictyostelium cells [15].

In AD patients with mutated PS1, Coupland et al. identified a decrease in the DNA methylation of the promoter for the gene encoding microtubule-associated protein tau (MAPT) as a common phenomenon in a specific brain-region of these AD patients [16].

3. Presenilins and Ca\textsuperscript{2+} Signaling

Dysfunction in Ca\textsuperscript{2+} signaling can contribute to age-related central nervous system (CNS) decline [17]. Such damage in brain aging, especially in AD, is thought to be the result of numerous micro-injuries such as oxidative damage in synapses and loss of Ca\textsuperscript{2+} homeostasis leading to increased cytosolic Ca\textsuperscript{2+} concentrations [18]. Long term potentiation is reduced following presynaptic (but not postsynaptic) deletion of presenilins mimicking the depletion of ER Ca\textsuperscript{2+} stores by RyR inhibitors [19]. Presynaptic presenilin deficiency also reduced evoked glutamate release, indicating that presenilins play a role in activity-dependent neurotransmitter release and that presynaptic dysfunction represents an early event in AD development [19].

Neurons expressing mutant PS1 exhibit an increase in calcineurin activity and inhibition or reversal of this elevated calcineurin activity stabilized GluA1 phosphorylation and improved homeostatic synaptic plasticity [20]. Improvement of homeostatic synaptic plasticity leads to attenuation of AD-related cognitive decline and likewise improvement in learning and memory [20]. A novel γ-secretase modulator (compound-1) reduces Aβ expression thus relieving cognitive dysfunction in Tg2576 APP transgenic mice, a common mouse model of AD [21]. In mice embryogenic fibroblast cells, this inhibitor also plays a role in Ca\textsuperscript{2+} signaling by enhancing long-term potentiation (LTP), an indicator of synaptic strength [21].

Presenilins are regulators of intracellular calcium stores. RyRs and IP\textsubscript{3}Rs, major intracellular Ca\textsuperscript{2+} channels residing in the ER, are regulated by PS proteins. Furthermore, the expression of ER resident Ca\textsuperscript{2+} channels is increased in neurons expressing mutant PS1 [20]. The presenilin–ryanodine receptor (PS–RyR) interaction, where PS1 and PS2 N-termini bind the cytoplasmic face of RyR, regulates channel activity [22] similar to the actions of other AD related proteins binding to the RyR [23]. Investigation of the expression patterns of PS1 and PS2 identified an overall decrease in PS1 level with increase in PS2 level in older mice [24].

A PS1 N-terminal fragment (NTF), which lacks four cysteine residues, decreased total RyR-mediated Ca\textsuperscript{2+} release, while a PS2 NTF, which contains four cysteine residues, had no effect [25]. These cysteines were mutated, allowing conversion of PS1 NTF function to PS2 NTF-like function and vice versa, likely based on differential RyR binding [25]. Inactivation of presenilin in the hippocampus has no effect on ER Ca\textsuperscript{2+} concentration, but in the absence of presenilin, RyR levels and function were decreased in the hippocampus [26]. This suggests a connection between presenilin and Ca\textsuperscript{2+} homeostasis via RyR, further supporting the idea that loss of Ca\textsuperscript{2+} homeostasis is an early pathologic injury in AD [26].
The effect of Aβ plaque proximity to disruptions in hippocampal pyramidal neuron Ca^{2+} signaling was investigated. No significant correlation between Aβ plaque proximity to cells with altered Ca^{2+} signaling was found [27]. These data suggest that early disruptions in pyramidal cell Ca^{2+} signaling occur through Aβ plaque-independent mechanisms [27]. Neuronal presenilins in Drosophila have no role on resting Ca^{2+} channels but cause deficits in intracellular Ca^{2+} stores [28]. In addition, calmodulin null mutations suppress presenilin-induced deficits in Ca^{2+} stores [28].

Lee et al., 2015, studied the notion that the mechanism by which PS1 deletion impacts AD was through lysosomal acidification [29]. Their studies revealed that an increased pH in the lysosomes of PS1 knockout (PS1KO) cells caused abnormal Ca^{2+} efflux from lysosomes, resulting in increased cytosolic Ca^{2+} concentrations [29]. Normalizing lysosomal pH restored Ca^{2+} homeostasis, but restored Ca^{2+} homeostasis in turn by itself did not result in adequate acidification of lysosomes or reverse proteolytic and autophagic effects. This led the authors to conclude that an instable lysosomal vesicular ATPase (vATPase) subunit in PS1-deficient cells causes the deficits in lysosomal autophagy [29].

4. Presenilins and Oxidative Stress

Oxidative stress is a contributing factor to Alzheimer Disease pathogenesis, with several theories supporting a connection between oxidative stress and the accumulation of Aβ [30]. As monomeric Aβ facilitates glutathione release from astrocytes, it potentially contributes to protection from oxidative stress, a function that is reduced with Aβ_{42} aggregation and subsequent depletion of monomeric Aβ_{42} [31]. Presenilins are involved in neuroprotection against oxidative stress [30]. PS1 was determined to be important for neurotrophic factor-mediated neuroprotection against excitotoxicity and oxidative stress and was not dependent on the role of PS1 in γ-secretase activity, as γ-secretase inhibitors lacked any effect on trypsin-induced neuroprotection [32]. This mechanism seems to stem from PS1 mutants being unable to use trypsin to subsequently rescue neurons from excitotoxicity by activating extracellular signal-regulated kinase 1/2 (ERK1/2) [32]. As expected, PS mutants inhibited neuronal protection against toxic insults [32]. Exposure of neurons to low concentrations (0.25 ppm) of ozone lead to significant increases in Aβ_{42} in mitochondrial fractions, reduction in Aβ_{40}, overexpression of PS2, and reductions in ADAM10 expression [30], suggesting that Aβ_{42} accumulation may be involved in mitochondrial dysfunction and subsequent oxidative stress [30]. Sarasija et al. also studied Ca^{2+} transfer, but instead investigated a presenilin analog SEL-12 which regulates ER Ca^{2+} homeostasis [32]. This role in mitochondrial damage did not require γ-secretase activity and amyloid plaques [33]. Interestingly, in Zebrafish, a truncated PS2 isoform, PSV2, is capable of activating the phosphatidylinositol-3-kinase pathway and thereby generates neuroprotection via insulin-like growth factor-1 and other receptors [35]. This raises the interesting notion that part of Aβ toxicity is the result of a depletion of Aβ_{42} subsequent to Aβ_{42} oligomerization and polymerization [35].

The effect of certain diabetes drugs on Aβ production and oxidative stress has been investigated. Administration of the insulin sensitizer, metformin, increases APP and presenilin expression via NF-κB activation [34]. In contrast, insulin administration antagonized the effects of metformin by decreasing Aβ levels and reducing oxidative stress and mitochondrial dysfunction [34]. Interestingly, monomeric Aβ_{42} is capable of activating the phosphatidylinositol-3-kinase pathway and thereby generates neuroprotection via insulin-like growth factor-1 and other receptors [35]. This raises the interesting notion that part of Aβ toxicity is the result of a depletion of Aβ_{42} subsequent to Aβ_{42} oligomerization and polymerization [35].

The relationship between mitochondrial function and chaperone-mediated RyR degradation in cardiomyocytes (as well as fibroblast number) was studied in AD patients with PS1 mutations [35]. Fibroblasts with the AD mutation had elevated Aβ_{42}, reduced ATP levels, reduced mitochondrial respiration, and impaired mitochondrial respiratory capacity [36].

Copper (Cu^{2+}) is important for enzymatic antioxidant activity, namely as a cofactor in the antioxidant enzyme superoxide dismutase (SOD) [37]. While PS1 and PS2 play roles in Cu^{2+} uptake, presenilin knockdown in Drosophila reduces Cu^{2+} levels and consequently decreases SOD [37]. These presenilin knockdown Drosophila were sensitive to SOD-inducing chemical paraquat, supporting the role of presenilin on SOD activity [37]. Interestingly, in Zebrafish, a truncated PS2 isoform, PSV2, is induced in spontaneous AD under hypoxic conditions and conditions of high cholesterol [38].
PSV2 normally increases \( \gamma \)-secretase activity [38]. Zebrafish possess another presenilin isoform, PS1IV, an isoform similar to PS2V in humans [38]. It is associated with changes in cytokine gene expression, such as IL1\( \beta \) and CCR5, and in addition, the absence of PS1IV under hypoxic conditions is associated with changes in vascular development, protein synthesis, Ca\(^{2+} \) homeostasis, and cell proliferation [38].

*Drosophila* presenilin interacts with the enzymes thiol-specific antioxidant (TSA) and proliferation-associated gene (PAG), both involved in cellular antioxidant activity, and thereby affects Notch signaling [39]. Transgenic presenilin expression in precursor cells of wing and sensory organ caused a Notch loss-of-function phenotype [38]. In fact, co-expression of presenilin with proteins resulted in a more severe and penetrant Notch loss-of-function phenotype than PS expression alone [39]. Such signaling mechanisms involved in inflammation appear to be of particular importance given the role inflammation has in AD development in the presence of high A\( \beta \) levels [40] and that other pathogenic signaling mechanism such as tau protein cleavage and of the formation of neurofibrillary tangles respond to intervention with antioxidants [41].

Pedrozo et al. induced chaperone-mediated autophagy (CMA) in cardiomyocytes with geldanamycin, which prevented the loss of RyR2 degradation, suggesting that presenilins were involved in this process [42]. Presenilins, therefore, are involved in CMA and can target oxidatively damaged RyR2 [42].

### 5. The Role of Presenilins in Proteasome Function and Autophagy

Presenilin has many roles including, but not limited to, RyR regulation and interaction with other regulatory pathways. Hwang et al. demonstrated that PS2 mutations can lead to NF-\( \kappa \)B mediated amyloidosis [43]. Presenilins have two roles: proteolysis-dependent activity in the \( \gamma \)-secretase complex and activities in cellular signaling that are independent of proteolytic activity [44]. The coupling of ubiquitin conjugation to endoplasmic reticulum degradation (CUE) ubiquitin binding domain of PS1 coordinates polyubiquitination at lysine 63 [45].

Recent studies determined the effect of presenilins in the autophagy/lysosome system and found that presenilin deficit led to a reduction in lysosomal Ca\(^{2+} \) stores regardless of lysosome accumulation, and prevention of the organization of two-pore channels 1 and 2 (TPC1 and TPC2) [46]. This indicates that modifications in lysosomal Ca\(^{2+} \) due to presenilin deficiency can lead to interference of autophagy [46]. In addition, genetic deletion or knockdown of presenilins can lead to a buildup of autophagosomes independent of \( \gamma \)-secretase activity [47]. Ablation of *Dictyostelium* presenilins lead to PS1-mediated restoration of the terminal differentiation of multiple cell types independent of its proteolytic effect [44]. Presenilin loss in *Dictyostelium* leads to elevated cAMP concentrations and elevated Ca\(^{2+} \) release, indicating that presenilins indeed regulate signaling pathways [44].

The impact of loss of PS1 activity on lysosomal alkalization and subsequent impairment of autophagosomal function was determined, but investigations were unable to identify presenilin involvement in controlling autophagy [48]. Studies of mice brains lacking PS, however, revealed a function for PS in regulating lysosomal formation [48].

*Tequila* and mammalian analog Prss12 gene expression is reduced by presenilins in brains of *Drosophila melanogaster* larvae and in mouse embryonic fibroblasts [49]. A mature \( \gamma \)-secretase complex was found to be essential for inhibiting neurotrypsin expression and reduction of agrin cleavage, but PS1 processing of \( \gamma \)-secretase substrates was not required for this activity [49]. Silencing of the *Drosophila* ortholog of presenilins (dPsn) lowered the heart rate, while dPSn overexpression increased it [50]. dPSN silencing also increased dIL3R expression and decreased dSERCA expression, while dPSn overexpression lowered dRyR expression [50]. All in all, changes in presenilin expression resulted in cardiac dysfunction via aberrant Ca\(^{2+} \) signaling and disrupted Wnt signaling [50] (summarized in Table 1).
**Table 1.** Presenilin function within cells.

| Presenilin Function       | Protein/Signaling Targets                                                                 | References                                      |
|---------------------------|------------------------------------------------------------------------------------------|------------------------------------------------|
| γ-secretase complex activity | APP                                                                                      | [2,6,7,10–15]                                  |
| Ca²⁺ signaling            | IP₃,R, RyR (mammalian); regulation of dIP₃,R, dSERCA and dRyR expression (Drosophila melanogaster); SEL-12 (Caenorhabditis elegans) | [4,17–22,25,26,28,29,33,46]                    |
| Oxidative stress          | trypsin-mediated ERK1/2 activation, mitochondrial proteins, thiol-specific antioxidant (TSA) and proliferation-associated gene (PAG) | [18,30,32,39,42]                               |
| Proteolysis               | Trypsin, CREB activity                                                                    | [32,49]                                       |
| Lysosome/Autophagy         | vATPase regulation, chaperone-mediated autophagy, two-pore calcium channel expression, lysosomal proteolysis, lysosomal acidification | [29,42,46–48]                                  |
| Cellular signaling        | Notch, inflammatory signaling                                                            | [38,39]                                       |
| Cellular differentiation/development | Proteolytic agrin cleavage                                                              | [15,44,49]                                   |

6. Functions of Presenilins Outside of AD

Besides its well-documented role in AD, presenilins also play many roles in other diseases (see Table 2). This results in both a more differentiated view of the involvement of PS and potentially opens up new avenues for drug targeting and drug discovery. The role of a gene, which interacts with PTEN-induced putative kinase in mitochondrial homeostasis and during early-onset Parkinson disease, called presenilin-associated rhomboid-like (PARL), was investigated [51]. Single nucleotide polymorphisms in PARL represented a rare cause of Parkinson disease [51].

Presenilin is also involved in variants of cancer, as PS1 was amplified in gastric cancer and correlated with a poor survival and increased metastasis [52]. This mechanism may be explained by the E-cadherin cleavage and β-catenin release by PS1, thus allowing β-catenin nuclear translocation and transcriptional activations to promote gastric cancer progression [52]. Fusion transcripts between large tumor suppressor 1 (LATS1) and PS1 genes were unable to phosphorylate yes-associated protein and subsequently inhibit the growth of malignant mesothelioma cells [53].

PS1 is also involved in the development of the skin disorder hidradenitis suppurativa or acne inversa. Defective Notch signaling due to loss of function mutations of PS-1 and other γ-secretase subunits likely contributes to the pathogenesis of hidradenitis suppurativa affecting integral membrane proteins such as Notch, E-cadherin, or CD44 [54]. A Mutation of PS2 was identified as a genetic cause for familial comedones syndrome, which has clinical phenotypes similar to hidradentis suppurativa [55].

While a clear link has been demonstrated between development of Alzheimer’s disease and increasing age, links have also been found between PS function and normal aging. A preclinical model for aging was used to identify changes in cerebellar and forebrain PS expression that correlate with performance in motor function, memory, and learning in aged rats, where PS1 was decreased while PS2 was increased [24]. Puig et al. identified the roles of mutant APP and PS1 in the enteric nervous system [56]. They found that APP/PS1 mice had normal gastrointestinal function, but they had higher luminal IgA and APP, indicating elevated proinflammatory factors and immune cell activation [56].

Presenilins also play a role in cardiac function. Chaperone-mediated autophagy (CMA), a process involved in the degradation of soluble proteins in the cytosol, occurs by lysosome associated membrane protein type 2A- (LAMP-2A)-facilitated degradation [42]. LAMP2 mutations can lead to Danon disease, characterized by hypertrophic cardiomyopathy [42]. Pedrozo et al. discovered that RyR2 is degraded by CMA, suggesting that oxidative damage targets RyR2 for turnover via presenilins and CMA [42]. Li et al. discovered that silencing the Drosophila ortholog of presenilins (dPsn) reduced heart rates and generated an age-dependent rise in end-diastolic vertical dimensions; conversely, dPsn overexpression
led to higher heart rates [50]. Silencing of dPsn elevated the expression levels of the *Drosophila* ortholog of IP₃R and reduced expression of the *Drosophila* ortholog of SERCA while overexpression of dPsn led to reduced expression of the *Drosophila* ortholog of the RyR [50], offering a mechanism for how cardiac dysfunction occurs via changes in PS expression. Overall, presenilin changes lead to cardiac dysfunction secondary to abnormal Ca²⁺ channel activity and disrupted Wnt signaling [50]. Presenilins also play a role in embryogenesis. Donoviel et al. generated PS1/PS2 double null mice and noticed embryonic lethality [57]. In addition, embryos deficient in both presenilins demonstrated developmental dysregulation such as absence of segmentation, defects in ventral neural tube formation, delays in the closure of the anterior neuropore, and irregular heart development [57].

### Table 2. Presenilin involvement in diseases and conditions.

| Disease/Condition                                      | System/Orgon       | References          |
|--------------------------------------------------------|--------------------|---------------------|
| Normal neuronal function (cognition, memory)           | Brain, intestine   | [19,21,24,26,28,32,42,43] |
| Alzheimer’s disease                                    | Brain              | [1,4–6,16,17,19]    |
| Parkinson’s disease                                    | Brain              | [51]                |
| Familial comedones                                     | Skin               | [54,55]             |
| Cancer                                                 | gastrointestinal   | [52,53]             |
| Cardiac dysfunction (embryonic development)            | heart              | [42,50,57]          |

### 7. Conclusions

Overall, the involvement of PS as part of the γ-secretase complex and in other roles in both excitable and non-excitable cells, but especially in immune cells such as T-cells and macrophages (Table 1), opens up a wide range of possible roles for PS as targets for AD drug target discovery and drug development (Table 2).

**Author Contributions:** P.K. conceived and designed the review; R.S.D., B.S. and P.K. wrote the paper.

**Acknowledgments:** This publication was supported in part by grants from the National Eye Institute (EY014227, EY022774 and EY027005), the National Institute on Aging (AG022550 and AG027956), the National Center for Research Resources and National Institute of General Medical Sciences (RR027093) of the National Institutes of Health (P.K.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support by the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research and a Challenge Grant from Research to Prevent Blindness (P.K.) is gratefully acknowledged.

**Conflicts of Interest:** The authors declare no conflict of interest.

### Abbreviations

- **Aβ**: amyloid beta
- **AD**: Alzheimer’s disease
- **APP**: amyloid precursor protein
- **CMA**: chaperone-mediated autophagy
- **CNS**: central nervous system
- **ER**: endoplasmic reticulum
- **ERK1/2**: extracellular signal-regulated kinase 1/2
- **FAD**: familial Alzheimer’s disease
- **IP₃R**: inositol 1,4,5-trisphosphate receptor
- **LAMP**: by lysosome associated membrane protein
- **LATS1**: large tumor suppressor 1
- **MAPT**: microtubule-associated protein tau
- **NTF**: N-terminal fragment
- **PS1**: presenilin 1
- **PS2**: presenilin 2
RyR  ryanodine receptor  
SOD  superoxide dismutase  
TPC  two-pore channels  

References 

1. Clark, R.F.; Hutton, M.; Fuldner, R.A.; Froelich, S.; Karran, E.; Talbot, C.; Crook, R.; Lendon, C.; Prihar, G.; He, C.; et al. The structure of presenilin 1(S182) gene and identification of six novel mutation in early onset AD families. Nat. Genet. 1995, 11, 219–222. [CrossRef] [PubMed] 
2. Xia, W.; Zhang, J.; Kholodenko, D.; Citron, M.; Podlisny, M.B.; Teplow, D.B.; Haass, C.; Seubert, P.; Koo, E.H.; Selkoe, D.J. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 1997, 272, 7977–7982. [CrossRef] [PubMed] 
3. Lasagna-Reeves, C.A.; Glabe, C.G.; Kayed, R. Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J. Biol. Chem. 2011, 286, 22122–22130. [CrossRef] [PubMed] 
4. Mattson, M.P.; Guo, Q.; Furukawa, K.; Pedersen, W.A. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer’s disease. J. Neurochem. 1998, 70, 1–14. [CrossRef] [PubMed] 
5. Roeber, S.; Müller-Sarnowski, F.; Kress, J.; Edbauer, D.; Kuhlmann, T.; Tüttelmann, F.; Schindler, C.; Winter, P.; Arzberger, T.; Müller, U.; et al. Three novel presenilin 1 mutations marking the wide spectrum of age at onset and clinical patterns in familial Alzheimer’s disease. J. Neural Transm. 2015, 122, 1715–1719. [CrossRef] [PubMed] 
6. Svedružić, Ž.M.; Popović, K.; Šendula-Jengić, V. Decrease in catalytic capacity of γ-secretase can facilitate pathogenesis in sporadic and Familial Alzheimer’s disease. Mol. Cell. Neurosci. 2015, 67, 55–65. [CrossRef] [PubMed] 
7. Moussavi Nik, S.H.; Newman, M.; Wilson, L.; Ebrahimie, E.; Wells, S.; Musgrave, I.; Verdile, G.; Martins, R.N.; Lardelli, M. Alzheimer’s disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of γ-secretase activity. Hum. Mol. Genet. 2015, 24, 3662–3678. [CrossRef] [PubMed] 
8. Somavarapu, A.K.; Kepp, K.P. The dynamic mechanism of presenilin-1 function: Sensitive gate dynamics and loop unplugging control protein access. Neurobiol. Dis. 2016, 89, 147–156. [CrossRef] [PubMed] 
9. Pardossi-Piquard, R.; Yang, S.P.; Kanemoto, S.; Gu, Y.; Chen, F.; Böhm, C.; Sevalle, J.; Li, T.; Wong, P.C.; Checler, F.; et al. APH1 polar transmembrane residues regulate the assembly and activity of presenilin complexes. J. Biol. Chem. 2009, 284, 16298–16307. [CrossRef] [PubMed] 
10. Svedružić, Z.M.; Popović, K.; Smoljan, I.; Šendula-Jengić, V. Modulation of γ-secretase activity by multiple enzyme-substrate interactions: Implications in pathogenesis of Alzheimer’s disease. PLoS ONE 2012, 7, e32293. [CrossRef] [PubMed] 
11. Marinangeli, C.; Tasiaux, B.; Opsomer, R.; Hage, S.; Sodero, A.O.; Dewachter, I.; Octave, J.N.; Smith, S.O.; Constantinescu, S.N.; Kienent-Campard, P. Presenilin transmembrane domain 8 conserved AXXXXAXXXG motifs are required for the activity of the γ-secretase complex. J. Biol. Chem. 2015, 290, 7169–7184. [CrossRef] [PubMed] 
12. Pozdnyakov, N.; Murrey, H.E.; Crump, C.J.; Pettersson, M.; Ballard, T.E.; Am Ende, C.W.; Ahn, K.; Li, Y.M.; Bales, K.R.; Johnson, D.S. γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J. Biol. Chem. 2013, 288, 9710–9720. [CrossRef] [PubMed] 
13. Park, H.J.; Shabashvili, D.; Nekorchuk, M.D.; Shyqyriu, E.; Jung, J.I.; Ladd, T.B.; Moore, B.D.; Felsenstein, K.M.; Golde, T.E.; Kim, S.H. Retention in endoplasmic reticulum 1 (RER1) modulates amyloid-β (Aβ) production by altering trafficking of γ-secretase and amyloid precursor protein (APP). J. Biol. Chem. 2012, 287, 40629–40640. [CrossRef] [PubMed] 
14. Jeon, A.H.; Böhm, C.; Chen, F.; Hoo, H.; Ruan, X.; Ren, C.H.; Ho, K.; Qamar, S.; Mathews, P.M.; Fraser, P.E.; et al. Interactome analyses of mature γ-secretase complexes reveal distinct molecular environments of presenilin (PS) paralogs and preferential binding of signal peptide peptidase to PS2. J. Biol. Chem. 2013, 288, 15352–15366. [CrossRef] [PubMed] 
15. McMains, V.C.; Myre, M.; Kreppel, L.; Kimmel, A.R. Dictyostelium possesses highly diverged presenilin/ gamma-secretase that regulates growth and cell-fate specification and can accurately process human APP: A system for functional studies of the presenilin/gamma-secretase complex. Dis. Models Mech. 2010, 3, 581–594. [CrossRef] [PubMed]
16. Coupland, K.G.; Kim, W.S.; Halliday, G.M.; Hallupp, M.; Dobson-Stone, C.; Kwok, J.B. Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer’s disease. Curr. Alzheimer Res. 2015, 12, 745–751. [CrossRef] [PubMed]

17. Mattson, M.P.; Rydel, R.E.; Lieberburg, I.; Smith-Swintosky, V.L. Altered calcium signaling and neuronal injury: Stroke and Alzheimer’s disease as examples. Ann. N. Y. Acad. Sci. 1993, 679, 1–21. [CrossRef] [PubMed]

18. Beal, M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38, 357–366. [CrossRef] [PubMed]

19. Zhang, C.; Wu, B.; Beglopoulos, V.; Wines-Samuelson, M.; Zhang, D.; Dragatis, I.; Südhof, T.C.; Chen, J. Presenilins are essential for regulating neurotransmitter release. Nature 2009, 460, 632–636. [CrossRef] [PubMed]

20. Grillo, M.A.; Grillo, S.L.; Gerdes, B.C.; Kraus, J.G.; Koulen, P. Control of Neuronal Ryanodine Receptor-Mediated Calcium Signaling by Calsenilin. Mol. Neurobiol. 2018, 1–10. [CrossRef] [PubMed]

21. Hayama, T.; Murakami, K.; Watanabe, T.; Maeda, R.; Kamata, M.; Kondo, S. Single administration of a novel γ-secretase modulator ameliorates cognitive dysfunction in aged C57BL/6 mice. Brain Res. 2016, 1633, 52–61. [CrossRef] [PubMed]

22. Payne, A.J.; Kaja, S.; Koulen, P. Regulation of ryanodine receptor-mediated calcium signaling by presenilins. Recept. Clin. Investig. 2015, e249.

23. Briggs, C.A.; Schneider, C.; Richardson, J.C.; Stutzmann, G.E. β amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer’s disease mice. Neurobiol. Aging 2013, 34, 1632–1643. [CrossRef] [PubMed]

24. Michno, K.; Knight, D.; Campusano, J.M.; van de Hoe, D.; Boulianne, G.L. Intracellular calcium deficits in Drosophila cholinergic neurons expressing wild type or FAD-mutant presenilin. Exp. Neurol. 2015, 250, 143–150. [CrossRef] [PubMed]

25. Wu, B.; Yamaguchi, H.; Lai, F.A.; Shen, J. Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hippocampal neurons. Proc. Natl. Acad. Sci. USA 2013, 110, 15091–15096. [CrossRef] [PubMed]

26. Lee, J.H.; McBrayer, M.K.; Wolfe, D.M.; Haslett, L.J.; Kumar, A.; Sato, Y.; Lie, P.P.; Mohan, P.; Coffey, E.E.; Kompella, U.; et al. Presenilin 1 Maintains Lysosomal Ca\textsuperscript{2+} Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep. 2015, 12, 1430–1444. [CrossRef] [PubMed]

27. Hernández-Zimbron, L.F.; Rivas-Aracibia, S. Oxidative stress caused by ozone exposure induces β-amyloid 1–42 overproduction and mitochondrial accumulation by activating the amyloidogenic pathway. Neuroscience 2015, 304, 340–348. [CrossRef] [PubMed]

28. Lee, J.H.; McBrayer, M.K.; Wolfe, D.M.; Haslett, L.J.; Kumar, A.; Sato, Y.; Lie, P.P.; Mohan, P.; Coffey, E.E.; Kompella, U.; et al. Presenilin 1 Maintains Lysosomal Ca\textsuperscript{2+} Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep. 2015, 12, 1430–1444. [CrossRef] [PubMed]

29. Ye, B.; Shen, H.; Zhang, J.; Zhu, Y.G.; Ransom, B.R.; Chen, X.C.; Ye, Z.C. Dual pathways mediate β-amyloid stimulated glutathione release from astrocytes. Glia 2015, 63, 2208–2219. [CrossRef] [PubMed]

30. Nikolakopoulou, A.M.; Georgakopoulos, A.; Robakis, N.K. Presenilin 1 promotes trypsin-induced neuroprotection via the PAR2/ERK signaling pathway. Effects of presenilin 1 FAD mutations. Neurobiol. Aging 2016, 42, 41–49. [CrossRef] [PubMed]

31. Sarasija, S.; Norman, K.R. A γ-Secretase Independent Role for Presenilin in Calcium Homeostasis Impacts Mitochondrial Function and Morphology in Caenorhabditis elegans. Genetics 2015, 201, 1453–1466. [CrossRef] [PubMed]

32. Picone, P.; Nuzzo, D.; Caruana, L.; Messina, E.; Barera, A.; Vasto, S.; Di Carlo, M. Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: Use of insulin to attenuate metformin’s effect. Biochim. Biophys. Acta 2015, 1853, 1046–1059. [CrossRef] [PubMed]
35. Giuffrida, M.L.; Caraci, F.; Pignataro, B.; Cataldo, S.; De Bona, P.; Bruno, V.; Molinaro, G.; Pappalardo, G.; Messina, A.; Palmigiano, A.; et al. Beta-amyloid monomers are neuroprotective. *J. Neurosci.* 2009, 29, 10582–10587. [CrossRef] [PubMed]

36. Gray, N.E.; Quinn, J.E. Alterations in mitochondrial number and function in Alzheimer’s disease fibroblasts. *Metab. Brain Dis.* 2015, 30, 1275–1278. [CrossRef] [PubMed]

37. Southon, A.; Greenough, M.A.; Ganio, G.; Bush, A.I.; Burke, R.; Camakaris, J. Presenilin promotes dietary copper uptake. *PloS ONE* 2013, 8, e62811. [CrossRef] [PubMed]

38. Ebrahimie, E.; Moussavi Nik, S.H.; Newman, M.; Van Der Hoek, M.; Lardelli, M. The Zebrafish Equivalent of Alzheimer’s Disease-Associated PRESENILIN Isoform PS2V Regulates Inflammatory and Other Responses to Hypoxic Stress. *J. Alzheimers Dis.* 2016, 52, 581–608. [CrossRef] [PubMed]

39. Wangler, M.F.; Reiter, L.T.; Zimm, G.; Trimble-Morgan, J.; Wu, J.; Bier, E. Antioxidant proteins TSA and PAG interact synergistically with Presenilin to modulate Notch signaling in Drosophila. *Protein Cell* 2011, 2, 554–563. [CrossRef] [PubMed]

40. Armstrong, R.A. β-amyloid (Aβ) deposition in cognitively normal brain, dementia with Lewy bodies, and Alzheimer’s disease: A study using principal components analysis. *Folia Neuropathol.* 2012, 50, 130–139. [PubMed]

41. Means, J.C.; Gerdes, B.C.; Koulou, P. Distinct Mechanisms Underlying Resveratrol-Mediated Protection from Types of Cellular Stress in C6 Glioma Cells. *Int. J. Mol. Sci.* 2017, 18, 1521. [CrossRef] [PubMed]

42. Pedrozo, Z.; Torrealba, N.; Fernández, C.; Gatica, D.; Toro, B.; Quiroga, C.; Rodríguez, A.E.; Sanchez, G.; Gillette, T.G.; Hill, J.A.; et al. Cardiomyocyte ryanodine receptor degradation by chaperone-mediated autophagy. *Cardiovasc. Res.* 2013, 98, 277–285. [CrossRef] [PubMed]

43. Hwang, C.J.; Park, M.H.; Choi, M.K.; Choi, J.S.; Oh, K.W.; Hwang, D.Y.; Han, S.B.; Hong, J.T. Acceleration of amyloidogenesis and memory impairment by estrogen deficiency through NF-κB dependent beta-secretase activation in presenilin 2 mutant mice. *Brain Behav. Immun.* 2016, 53, 113–122. [CrossRef] [PubMed]

44. Ludtmann, M.H.; Otto, G.P.; Schilde, C.; Chen, Z.H.; Allan, C.Y.; Brace, S.; Beesley, P.W.; Kimmel, A.R.; Fisher, P.; Killick, R.; et al. An ancestral non-proteolytic role for presenilin proteins in multicellular development of the social amoeba Dictyostelium discoideum. *J. Cell Sci.* 2014, 127, 1576–1584. [CrossRef] [PubMed]

45. Duggan, S.P.; Yan, R.; McCarthy, J.V. A ubiquitin-binding CUE domain in presenilin-1 enables interaction with K63-linked polyubiquitin chains. *FEBS Lett.* 2015, 589, 1001–1008. [CrossRef] [PubMed]

46. Neely Kayala, K.M.; Dickinson, G.D.; Minassian, A.; Walls, K.C.; Green, K.N.; Laferla, F.M. Presenilin-null cells have altered two-pore calcium channel expression and lysosomal calcium: Implications for lysosomal function. *Brain Res.* 2012, 1489, 8–16. [CrossRef] [PubMed]

47. Neely, K.M.; Green, K.N.; Laferla, F.M. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner. *J. Neurosci.* 2011, 31, 2781–2791. [CrossRef] [PubMed]

48. Zhang, X.; Garbett, K.; Veeraraghavalu, K.; Wilburn, B.; Gilmore, R.; Mirnics, K.; Sisodia, S.S. A role for presenilins in autophagy revisited: Normal acidification of lysosomes in cells lacking PSEN1 and PSEN2. *J. Neurosci.* 2012, 32, 8633–8648. [CrossRef] [PubMed]

49. Almenar-Queralt, A.; Kim, S.N.; Benner, C.; Herrera, C.M.; Kang, D.E.; Garcia-Bassets, I.; Goldstein, L.S. Presenilins regulate neurotyspin gene expression and neurotyspin-dependent agrin cleavage via cyclic AMP response element-binding protein (CREB) modulation. *J. Biol. Chem.* 2013, 288, 35222–35236. [CrossRef] [PubMed]

50. Li, A.; Zhou, C.; Moore, J.; Zhang, P.; Tsai, T.H.; Lee, H.C.; Romano, D.M.; McKee, M.L.; Schoenfeld, D.A.; Serra, M.J.; et al. Changes in the expression of the Alzheimer’s disease-associated presenilin gene in drosophilia heart leads to cardiac dysfunction. *Curr. Alzheimer Res.* 2011, 8, 313–322. [CrossRef] [PubMed]

51. Wüst, R.; Maurer, B.; Hauser, K.; Woitalla, D.; Sharma, M.; Krüger, R. Mutation analyses and association studies to assess the role of the presenilin-associated rhomboid-like gene in Parkinson’s disease. *Neurobiol. Aging* 2016, 39, 217.

52. Li, P.; Lin, X.; Zhang, J.R.; Li, Y.; Lu, J.; Huang, F.C.; Zheng, C.H.; Xie, J.W.; Wang, J.B.; Huang, C.M. The expression of presenilin 1 enhances carcinogenesis and metastasis in gastric cancer. *Oncotarget* 2016, 7, 10650–10662. [CrossRef] [PubMed]
53. Miyanaga, A.; Masuda, M.; Tsuta, K.; Kawasaki, K.; Nakamura, Y.; Sakuma, T.; Asamura, H.; Gemma, A.; Yamada, T. Hippo pathway gene mutations in malignant mesothelioma: Revealed by RNA and targeted exon sequencing. *J. Thorac. Oncol.* **2015**, *10*, 844–851. [CrossRef] [PubMed]

54. Prens, E.; Deckers, I. Pathophysiology of hidradenitis suppurativa: An update. *J. Am. Acad. Dermatol.* **2015**, *73*, S8–S11. [CrossRef] [PubMed]

55. Panmontha, W.; Rerknimitr, P.; Yeetong, P.; Srichomthong, C.; Suphapeetiporn, K.; Shotelersuk, V. A Frameshift Mutation in PEN-2 Causes Familial Comedones Syndrome. *Dermatology* **2015**, *231*, 77–81. [CrossRef] [PubMed]

56. Puig, K.L.; Lutz, B.M.; Urquhart, S.A.; Rebel, A.A.; Zhou, X.; Manocha, G.D.; Sens, M.; Tuteja, A.K.; Foster, N.L.; Combs, C.K. Overexpression of mutant amyloid-β protein precursor and presenilin 1 modulates enteric nervous system. *J. Alzheimers Dis.* **2015**, *44*, 1263–1278. [PubMed]

57. Donoviel, D.B.; Hadjantonakis, A.K.; Ikeda, M.; Zheng, H.; Hyslop, P.S.; Bernstein, A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. *Genes Dev.* **1999**, *13*, 2801–2810. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).